Russian-born Tagziev, who won the 86 kilogram freestyle division at Glasgow 2014 and then earned bronze at last year’s Pan American Games in Toronto, was found to have traces of the heart-attack drug in an in-competition sample given back in May.

The CCES - Canada’s anti-doping agency - confirmed in a statement that Tagziev, who emigrated from Russia and now lives in Toronto, had not "engaged in the results process".

"In accordance with the Canadian Anti-Doping Program (CADP), if an athlete does not engage in the results process, the anti-doping rule violation and sanction are confirmed by way of a deemed waiver," the CCES added.

The 34-year-old has been ruled out of competing until August 9, 2020, which could spell the end of his career in the sport.

He did not compete for Canada at the Rio 2016 Olympic Games.

A number of athletes have had suspensions lifted following positive tests for meldonium, which is manufactured in Latvia and was added to the World Anti-Doping Agency (WADA) banned list on January 1, in recent months.

It came after WADA extended the period during which athletes may escape punishment if they tested positive for meldonium from March 1 to September 30.

Under the updated guidance, athletes who provided a urine sample which returned a positive test for the heart-attack drug between January 1 and February 29 can also be given a “no fault” verdict if their sample contained less than five micrograms of meldonium.

This marked an increase from the previous set of guidelines published by WADA, which stated if below one microgram of meldonium was detected and the failed test came before March 1, a negligence or no fault verdict could be reached.

WADA had published an earlier clarification on meldonium in April, leading to criticism of the governing body as some claimed they had handled the situation poorly.

It followed uncertainty over how long the substance stayed in the body.